NEWS HIGHLIGHTS
Published Studies Related to Glucotrol (Glipizide)
Lipid profiling reveals different therapeutic effects of metformin and glipizide
in patients with type 2 diabetes and coronary artery disease. [2014] CONCLUSIONS: Our findings revealed the differential therapeutic effects of
Effects of metformin versus glipizide on cardiovascular outcomes in patients with
type 2 diabetes and coronary artery disease. [2013] CONCLUSIONS: Treatment with metformin for 3 years substantially reduced major
Effects of Metformin Versus Glipizide on Cardiovascular Outcomes in Patients With
Type 2 Diabetes and Coronary Artery Disease. [2012] OBJECTIVEThe two major classes of antidiabetic drugs, sulfonylureas and
metformin, may differentially affect macrovascular complications and mortality in
diabetic patients. We compared the long-term effects of glipizide and metformin
on the major cardiovascular events in type 2 diabetic patients who had a history
of coronary artery disease (CAD).RESEARCH DESIGN AND METHODSThis study is a
multicenter, randomized, double-blind, placebo-controlled clinical trial...
Dapagliflozin versus glipizide as add-on therapy in patients with type 2 diabetes who have inadequate glycemic control with metformin: a randomized, 52-week, double-blind, active-controlled noninferiority trial. [2011.09] CONCLUSIONS: Despite similar 52-week glycemic efficacy, dapagliflozin reduced weight and produced less hypoglycemia than glipizide in type 2 diabetes inadequately controlled with metformin. Long-term studies are required to further evaluate genital and urinary tract infections with SGLT2 inhibitors.
Meal fat storage in subcutaneous adipose tissue: comparison of pioglitazone and glipizide treatment of type 2 diabetes. [2010.10] Treatment of type 2 diabetes (T2DM) with pioglitazone changes abdominal fat in the opposite direction as treatment with glipizide. To determine whether these two medications affect adipose tissue meal fatty acid storage differently we studied 19 T2DM treated with either pioglitazone (n = 8) or glipizide (n = 11) and 11 non-DM control subjects matched for age, BMI, abdominal and leg fat...
Clinical Trials Related to Glucotrol (Glipizide)
Sitagliptin Versus Glipizide in Participants With Type 2 Diabetes Mellitus and Chronic Renal Insufficiency (MK-0431-063 AM1) [Completed]
The purpose of the study is to compare how sitagliptin and glipizide lower blood glucose
levels in participants with moderate or severe renal insufficiency.
To Demonstrate the Relative Bioequivalency Comparing Geneva's 10 mg Glipizide Tablets To Roerig's 10 mg Glucotrol Tablets [Completed]
Efficacy and Safety of Alogliptin Compared to Glipizide in Elderly Diabetics [Completed]
The purpose of this study is to evaluate the efficacy and safety of alogliptin, once daily
(QD), compared to glipizide in elderly diabetic patients who have not received treatment or
are on a single oral medication.
Sitagliptin Versus Glipizide in Participants With Type 2 Diabetes Mellitus and End-Stage Renal Disease (MK-0431-073 AM1) [Completed]
The purpose of the study is to compare sitagliptin and glipizide in lowering blood sugar in
participants with type-2 diabetes mellitus (T2DM) and end-stage renal disease on dialysis
who do not have adequate glycemic control.
Cytochrome P450 2C19 Variant is Related to Pharmacokinetics of Glipizide Extended Release Tablet in Chinese Subjects [Completed]
Diabetes mellitus is a growing global disease now and future, and in China, 1. 2 million
peoples per year have been diagnosed as diabetes mellitus. 90% diabetes mellitus patient is
Type 2 diabetes mellitus. Glipizide is a potent drug to service patients who suffer from
Type 2 disease. Little information has been presented for the relationship between CYP2C19
genetic polymorphism and glipizide, since recently the investigators reported that there
existed a tendency. In this study the investigators found that CYP2C19 polymorphism
significantly influenced the pharmacokinetics of glipizide.
Reports of Suspected Glucotrol (Glipizide) Side Effects
Blood Glucose Increased (15),
Death (12),
Pain (10),
Pain in Extremity (8),
Malaise (7),
Gait Disturbance (7),
Pruritus (6),
Drug Ineffective (6),
Atrial Fibrillation (6),
Lung Disorder (6), more >>
|